Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BlueJays9293on Dec 19, 2023 7:43pm
131 Views
Post# 35792844

RE:RE:Exciting Developments Unveiled: A Deep Dive into Spectral's

RE:RE:Exciting Developments Unveiled: A Deep Dive into Spectral's For me, one of the most interesting and overlooked points of their latest update was that they are screeniing 100+ patients per week (third bullet point at the top).  That's a really strong number to me and I can only wonder if it's just bad luck that only one in a hundred gets past all the exclusion check points and then officially entered into Tigris.  I could swear that in one of their prior presentations that they had a slide that showed that Euphrates had a conversion rate of 2 to 2.5% of patients screened.  Unfortuanetely I can't find that slide but it does make me wonder why only 1% of patients screened are officially getting entered into the trial.  Are they being super vigilante to protect their already very strong ARR, are patients getting screened but their EAA is above .9, or are they just plain unlucky?  I don't know but I wish I could find that slide if anybody happenned to save it.  Eitherway if the mean reverts back to anything close to a Euphrates average of 2% conversion rate or hell even a 1.5% rate, well then things could quickly uptick our way.  I'm not saying it will happen, I'm just saying that it's not so outlandish to think that two instead of one gets converted and entered into Tigris for every hundred screened.  Anyways it's just something that caught my eye.        
<< Previous
Bullboard Posts
Next >>